Abstract
We report moderate effectiveness of influenza vaccination in previously healthy children aged from 6 months to 12 years in the 2018-2019 season.
Introduction
Influenza remains a significant global health challenge, causing substantial morbidity and mortality annually. In response, the South Korean government expanded its National Immunization Program (NIP) during the 2018–2019 season to include free vaccinations for all children aged 6 months to 12 years. While such policy expansions aim to enhance herd immunity and protect the most vulnerable, the real-world "field" effectiveness of these vaccines can vary significantly based on the match between vaccine strains and circulating viruses, as well as population-specific factors.
This study addresses a critical data gap regarding the Vaccine Effectiveness (VE) following this NIP expansion. By analyzing data from a pediatric Emergency Department (ED) at a tertiary hospital, the researchers provide a high-acuity snapshot of vaccine performance in children presenting with influenza-like illnesses (ILI).
Methods and Data Selection
The study utilized a test-negative design (TND), the gold standard for observational VE research. This approach compares patients who test positive for influenza (cases) with those who test negative (controls) among those presenting with similar respiratory symptoms. This design effectively controls for healthcare-seeking behavior, as both groups sought medical attention for their illness.
Data were retrospectively collected from the pediatric ER of Samsung Medical Center in Seoul between October 2018 and May 2019. Influenza detection was performed using the BD Veritor™ system, a rapid chromatographic immunoassay. To estimate VE, the team employed multivariate logistic regression to calculate adjusted Odds Ratios (aOR), adjusting for age, sex, and underlying medical conditions. The final VE was calculated as $VE = (1 - aOR) \times 100\%$.
The initial dataset included 2,901 pediatric ER visits. After excluding infants under 6 months (who were ineligible for vaccination) and patients with unknown vaccination status, the final cohort consisted of 1,692 visits from 1,417 unique patients.
Key Results
The study found an overall VE of 36.4% (95% CI, 13.9 to 53.1). When broken down by virus type, the vaccine showed 37.6% effectiveness against Influenza A and 24.0% against Influenza B, though the latter did not reach statistical significance.
The "Healthy Advantage"
A critical finding was the disparity in protection based on the child's health status. Previously healthy children experienced a VE of 47.8%, whereas children with underlying medical conditions showed a VE of -1.8%, indicating virtually no statistical protection in this high-risk group. This suggests that underlying diseases may blunt the immune response to the vaccine, or that these children require different immunization strategies.
Seasonality and Strain Mismatch
The 2018–2019 season in Korea was characterized by a bimodal distribution: a dominant Influenza A wave in December followed by a smaller Influenza B wave in April. The relatively lower effectiveness against Influenza B was attributed to a lineage mismatch; while the vaccine targeted the Yamagata lineage, the circulating virus was predominantly the Victoria lineage (36.8% vs 0.4% Yamagata).
Discussion and Limitations
The study confirms that the NIP expansion provided meaningful, albeit moderate, protection to school-aged children. However, several limitations must be considered. The retrospective nature of the study relied on parental recall for vaccination history, which may introduce bias. Additionally, the use of rapid antigen tests, while practical in an ER setting, is less sensitive than RT-PCR, potentially leading to an underestimation of VE due to false negatives in the control group.
Furthermore, the sample size for certain subgroups, such as adolescents (13–18 years) and specific chronic disease categories, was limited, resulting in wide confidence intervals.
Conclusion
The 2018-2019 season demonstrated that the expanded NIP in South Korea successfully offered moderate protection to a broad pediatric population. Future surveillance should prioritize prospective designs using PCR-confirmed cases and centralized vaccination registries to provide more precise estimates of vaccine impact, particularly for high-risk pediatric populations.
Summary updated